Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen in High Risk Statin Intolerant Subjects
NCT00707746Phase 2Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Oct 2008
- Primary completion
- Aug 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing Mipomersen with Placebo (2 arms). Primary endpoints: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at Week 28, Low-density Lipoprotein Cholesterol at Baseline and Primary Efficacy Time Point at Week 28 and 1 more. Started Oct 2008; status: completed.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00707746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707746.